B Group, Inc. Cellectis S.A. Put Options Transaction History
B Group, Inc.
- $117 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CLLS
# of Institutions
30Shares Held
15MCall Options Held
0Put Options Held
0-
Ubs Asset Management Americas Inc Chicago, IL4.72MShares$6.9 Million0.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$6.89 Million0.2% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.1 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$331,2370.0% of portfolio
-
Baillie Gifford & CO139KShares$203,0080.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $66.4M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...